RPRX
Royalty Pharma Plc
NASDAQ · Healthcare · Biotechnology · US
$67.30
−0.40%Price chart
Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29Nov 3Nov 6
Key dataNov 6, 2026
Open$66.63
From 52W high−0.40%
Volume4.81M
Market cap$29.97B
P/E (TTM)39.8x
P/S (TTM)11.5x
Div yield1.37%
Key dataNov 6, 2026
Open
$66.63
From 52W high
−0.40%
Volume
4.81M
Market cap
$29.97B
ValuationView details →
P/E (Fwd)
13.2x
EV/EBITDA
26.5x
P/E (TTM)
39.8x
RSI (14)
75.3
MomentumView details →
1D Return
−0.40%
YTD Return
+75.75%
SummaryUpdated Sep 1, 2026
Royalty Pharma plc (NASDAQ:RPRX) is a leading buyer of biopharmaceutical royalties and funder of innovation in the healthcare industry. Founded in 1996 and based in New York, the company went public in June 2020. Royalty Pharma operates as a specialized investment firm that acquires royalty streams from successful pharmaceutical and biotechnology products, providing capital to innovators while generating returns for shareholders through predictable cash flows from marketed therapies and development-stage products.
Similar companies
Latest newsMore news →
Royalty Pharma plc reported quarterly earnings of $1.21 per share, compared with $1.17 per share a year earlier.3d agoRoyalty Pharma plc raised its full-year 2026 Portfolio Receipts guidance to $3.5 billion–$3.55 billion.3d agoRoyalty Pharma plc reported third-quarter 2026 Portfolio Receipts of $890 million, up 9%, Royalty Receipts growth of 9%, and net cash provided by operating activities of $686 million.3d ago